Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09JES
|
|||
Former ID |
DNC001270
|
|||
Drug Name |
Sampatrilat
|
|||
Synonyms |
AC1L2YMI; SCHEMBL49065; C26H40N4O9S; UK 81252; LS-172743; (3R)-3-[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]-4-[1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]cyclopentyl]butanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hypotension [ICD-11: BA20-BA21] | Phase 2 | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C26H40N4O9S
|
|||
Canonical SMILES |
CS(=O)(=O)NC(CCCCN)C(=O)NCC(CC1(CCCC1)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)O)C(=O)O
|
|||
InChI |
1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1
|
|||
InChIKey |
LPUDGHQMOAHMMF-JBACZVJFSA-N
|
|||
CAS Number |
CAS 129981-36-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neutral endopeptidase (MME) | Target Info | Modulator | [1], [2] |
KEGG Pathway | Renin-angiotensin system | |||
Hematopoietic cell lineage | ||||
Protein digestion and absorption | ||||
Alzheimer's disease | ||||
NetPath Pathway | EGFR1 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
Primary Focal Segmental Glomerulosclerosis FSGS | ||||
Alzheimers Disease |
References | Top | |||
---|---|---|---|---|
REF 1 | Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71. | |||
REF 2 | Sampatrilat Shire. Curr Opin Investig Drugs. 2002 Apr;3(4):578-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.